1. A class action lawsuit has been filed against Biohaven Ltd. 2. The lawsuit claims securities fraud affecting investors from March 2023 to May 2025. 3. Allegations include overstated regulatory prospects for product candidates. 4. Investors could seek recovery without upfront costs or fees. 5. The firm Levi & Korsinsky has a strong track record in securities litigation.
Securities lawsuits typically lead to negative investor sentiment and reduced stock prices. Historical examples show similar cases impacting biotech stocks adversely.
Legal actions can lead to financial uncertainty for the company. Ongoing litigation may distract from operational goals and R&D investments.
Immediate negative legal developments can result in swift stock price responses. Past events have demonstrated rapid declines following news of legal actions.
NEW YORK, Aug. 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Biohaven Ltd. ("Biohaven Ltd." or the "Company") (NYSE:BHVN) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Biohaven Ltd. investors who were adversely affected by alleged securities fraud between March 24, 2023 and May 14, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/biohaven-ltd-lawsuit-submission-form?prid=161430&wire=4
BHVN investors may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (i) The company's product candidate, troriluzole's regulatory prospects as a treatment for SCA, and/or the sufficiency of data that Biohaven submitted in support of troriluzole's regulatory approval for this indication, were overstated; (ii) BHV-7000's efficacy and clinical prospects as a treatment for bipolar disorder were likewise overstated; (iii) all the foregoing, once revealed, was likely to have a significant negative impact on Biohaven's business and financial condition; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times.
WHAT'S NEXT? If you suffered a loss in Biohaven Ltd. during the relevant time frame, you have until September 12, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/class-action-filed-against-biohaven-ltd-bhvn-seeking-recovery-for-investors--contact-levi--korsinsky-302530698.html
SOURCE Levi & Korsinsky, LLP